The World Health Organisation (WHO) reveals that every year, cancer claims more than 10 million lives worldwide, per a Forbes report. An important hurdle in the fight against this deadly disease is the alarming rate of incomplete reporting in cancer trials. It is observed that up to 61% of completed trials fail to report critical outcomes, hindering progress due to flawed data, as highlighted by JCE. However, a promising new approach to monitoring data in oncology trials is being developed. Karnaditya Rana, a seasoned Clinical Data Management expert, has been working on these challenges, envisioning a future where advanced data practices assist global healthcare to thrive, offering renewed hope to patients.
The healthcare industry worldwide struggles with difficulties in conducting oncology trials. To top the list of obstacles stands data integrity, with a study suggesting that many trials experience more than 12-month delays, often because of data mismanagement, and a deficit in monitoring and compliance operations, per a 2024 Journal of Clinical Oncology. Traditional manual monitoring, which included regular site visits along with 100% source data verification, could account for up to 30% of a clinical trial’s expenditures, potentially costing sponsors hundreds of millions to more than a billion dollars every year. The inclusion of real-world data from diverse sources like labs, hospitals, and patient logs adds significant complexity, straining existing resources.
A more serious worry is the lack of focus in data analysis, leading to wasted efforts on insignificant details while missing critical issues. At the same time, increasing global regulations intensify the problem, with many trials failing to meet the compliance standards. This failure delays the drug approval of potentially life-saving drugs. As per PharmaTimes, particular monitoring issues are faced in observational real-world trials, especially regarding data quality and oversight. These delays impede the delivery of vital treatments, mainly for aggressive cancers like lung and gastrointestinal cancers, where time holds supreme importance. This landscape requires a more precise and targeted approach to address the urgency of the patient’s demands and keep their hope alive.
A clinical data management veteran, Karnaditya Rana, with more than eight years of experience, is bringing fresh ideas to tackle the challenges of oncology trials. During his career span, he has worked on complex studies on cancers such as lung and gastrointestinal types, where his noteworthy discovery was identifying the flaws in traditional monitoring systems. He implemented a risk-based monitoring (RBM) strategy instead of following the conventional approaches. This practical shift focused on monitoring efforts on critical data points like safety markers and lab results, decreasing the intensity of monitoring for less critical aspects.
His approach includes identifying the data areas most crucial to quality improvement and then tailoring monitoring activities accordingly. This change doesn’t just save time but also stimulates commercial growth by speeding up drug approvals, allowing pharmaceutical companies to enter global markets more rapidly. Downstream sectors, including drug suppliers and medical device makers, benefit as supply chains adjust to the increased demand, promoting international trade. This offers huge payoffs for society, potentially reducing the 10 million cancer deaths every year, by providing quicker access to treatments, especially in underserved regions where delays have the greatest impact.
“I noticed how much effort went into checking everything, even the small aspects, while bigger problems slipped through,” Rana shares. “Risk-based monitoring allows for a focused approach, concentrating on what really matters, keeping trials on track without losing them.”
His system employs automated flags to identify high-risk information, cutting down the need for manual reviews. This innovative solution has broad implications, promoting health equity by bringing therapies in underserved, low-income regions where delays in trial are a life or death issue. From a commercial point of view, it reduces billions of dollars of annual cost associated with inefficiency, thereby guiding growth in a multi-billion-dollar sector.
His methods also support collaborations across countries, as standardized RBM practices can be taken up by trial teams in Asia, Africa and other nations. This scalability has helped the retail industry get ready for increased demand, while pharmaceutical companies gain a competitive advantage in markets anticipating advanced treatments. By streamlining processes and operations, his methods guide a more reliable global supply chain, making sure that the medical products reach the most remote regions as well. Faster approvals deliver early interventions, cutting lung cancer mortality by a significant percentage in high-burden regions such as Southeast Asia, as per World Health Organisation predictions. Rana’s ideas lay a foundation for a space where data supports progress, eliminating delays.
Peeling back the layers, Rana’s risk-based monitoring hinges on a smart setup that curtails monitoring efforts remarkably while raising data quality. He taps into sharp data validation tricks during User Acceptance Testing (UAT) to spot risks, shaving response times for fixes down by a substantial amount. His system on electronic data capture (EDC) platforms integrates external data, such as lab outcomes and ctDNA assays, employing a self-tuning mechanism that shifts focus based on live risk levels. This ditches the one-size-fits-all check, putting effort where it counts most.
The technical know-how is evident in Rana’s ability to integrate unorganised data streams, aligning with global rules like ICH-GCP. He leans on a NoSQL engine to handle the jumble of unstructured data from observational trials, managing thousands of patient records with ease. This also cuts database lock times, saving months in trial schedules. Speeding up the development and approval of new cancer drugs can significantly decrease the typical 10-15 year timeline, saving hundreds of thousands of life-years globally by allowing earlier access to life-saving treatments.
With faster approvals allowing drug makers to join a mammoth oncology market, which is more than $200 billion and annually growing at around 11%, per Fortune Business Insights, 2024 has huge commercial impact. Meanwhile, medical product companies are progressing more sharply, with a $510 billion global market that is expected to expand at nearly 6% each year, supported by increasing healthcare demand. This boosts trade worldwide, with nations getting faster access to life-saving tools. Furthermore, supporting regulatory alignment, Rana’s methods are helping nations worldwide meet strict standards and share data more efficiently.
Scaling beyond trials, his approach offers a model for other health fields confronting data overload. It strengthens world health networks by ensuring consistency, data flow reliability, and guiding policy and resource allocation. The hundreds of millions in annual inefficiency cuts free up funds for research and patient care, increasing societal gains. This advanced framework doesn’t just fix present-day trials, but it also sets a standard for future health innovations.
The risk-based monitoring project of Karnaditya Rana points out a pivotal turn for global oncology trials, reducing delays and enhancing data reliability. Its impact stretches far and wide, with faster drug approvals supporting a billion-dollar market, stabilizing retail supply chains, and saving lives, cutting the chances of lung cancer deaths in weaker regions. Looking forward, this model aims to assist and alter the health research across the world, suggesting a blueprint for handling data issues in other diseases too. With the trials evolving, his approach could help create a terrain where treatments reach every part of the world on time, using data as a lifeline for millions.
